Abiraterone Acetate trials for Prostate cancer

All Abiraterone Acetate trials · All Prostate cancer trials

Phase breakdown

Recruiting trials studying Abiraterone Acetate for Prostate cancer

• A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
  NCT07198633 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
  NCT07005154 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 54 locations
• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
  NCT05593497 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 9 locations
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 330 locations
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 151 locations
• A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
  NCT07406282 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 1 location
• Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
  NCT05422911 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 12 locations
• Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
  NCT04947254 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
  NCT03833921 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
  NCT06384222 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
  NCT05406999 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
  NCT05393791 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 19 locations
• Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
  NCT04175431 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
  NCT06650579 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 4 locations
• Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
  NCT06369610 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  NCT06136624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 288 locations
• Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
  NCT04734730 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
  NCT06616597 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location

Common questions

How many trials study Abiraterone Acetate for Prostate cancer?

19 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.